v3.26.1
Collaborative and Other Relationships - Genesis (Details) - USD ($)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 6 Months Ended
May 31, 2026
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
[1]
License Agreements            
Research and development   $ 516,950 $ 494,917 $ 1,032,853 $ 932,196  
Prepaid expenses and other current assets   253,087   253,087   $ 317,831
Other assets, net   $ 86,759   $ 86,759   $ 18,166
Genesis Molecular AI            
License Agreements            
Payment to acquire license agreement $ 120,000          
Collaborative arrangement upfront payment 80,000          
Collaborative arrangement, term   5 years   5 years    
Research and development   $ 2,700   $ 2,700    
Prepaid expenses and other current assets   16,000   16,000    
Other assets, net   $ 61,300   $ 61,300    
Genesis Molecular AI | Development Milestones            
License Agreements            
Maximum aggregate milestone payments 135,000          
Genesis Molecular AI | Regulatory Milestone            
License Agreements            
Maximum aggregate milestone payments 475,000          
Genesis Molecular AI | Commercialization Milestones            
License Agreements            
Maximum aggregate milestone payments 550,000          
Genesis Molecular AI | Investment in Genesis            
License Agreements            
Equity investment $ 40,000          
Investment owned (in shares) 4.3          
Per share price (in USD per share) $ 9.332          
[1] The condensed consolidated balance sheet at December 31, 2025 has been derived from the audited consolidated financial statements at that date.